Summary
Support for Endometriosis Advocacy: TransLucent totally supports our CEO Steph Richards in her mission to secure increased funding and political priority for endometriosis research.
Support for Endometriosis Advocacy: A Statement from TransLucent
Following recent press coverage, we wish to reaffirm our full support for our CEO, Steph Richards, as she champions increased funding and research for endometriosis.
Steph’s mission in Parliament is as straightforward as it is vital: ensuring policymakers finally prioritise a condition that has been chronically underfunded and overlooked. Endometriosis can upend lives, causing debilitating pain, delayed diagnoses, and significant challenges both at work and at home. Real progress only occurs when the issue remains at the forefront of the political agenda—an area where Steph’s advocacy excels.
For years, Steph has worked tirelessly and voluntarily to bridge the resource and understanding gaps. Amid the noise of public debate, the core question remains simple:
Do women with endometriosis benefit when their needs receive more political attention, or less?
The answer is clear.
Strong advocacy ensures that women’s health is treated with the urgency it deserves.
While some critics focus on the messenger rather than the message, what truly matters is the persistence required to be heard by those in power. Steph’s efforts are rooted in supporting those who have waited far too long for proper recognition and treatment.
It should not be controversial to fight for better care. By keeping the pressure on Parliament, Steph is addressing a health crisis that has been sidelined for decades. TransLucent remains committed to backing every serious effort to improve the lives of those affected by endometriosis, and we stand firmly against any attempts to undermine the advocates working for that change.
